CA3220751A1 - Methods of treating breast cancer - Google Patents

Methods of treating breast cancer Download PDF

Info

Publication number
CA3220751A1
CA3220751A1 CA3220751A CA3220751A CA3220751A1 CA 3220751 A1 CA3220751 A1 CA 3220751A1 CA 3220751 A CA3220751 A CA 3220751A CA 3220751 A CA3220751 A CA 3220751A CA 3220751 A1 CA3220751 A1 CA 3220751A1
Authority
CA
Canada
Prior art keywords
patients
olaparib
breast cancer
treatment
placebo
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3220751A
Other languages
English (en)
French (fr)
Inventor
Anitra FIELDING
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
AstraZeneca AB
Original Assignee
AstraZeneca AB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by AstraZeneca AB filed Critical AstraZeneca AB
Publication of CA3220751A1 publication Critical patent/CA3220751A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
CA3220751A 2021-06-02 2022-05-31 Methods of treating breast cancer Pending CA3220751A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195795P 2021-06-02 2021-06-02
US63/195,795 2021-06-02
PCT/EP2022/064697 WO2022253800A1 (en) 2021-06-02 2022-05-31 Methods of treating breast cancer

Publications (1)

Publication Number Publication Date
CA3220751A1 true CA3220751A1 (en) 2022-12-08

Family

ID=82117716

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3220751A Pending CA3220751A1 (en) 2021-06-02 2022-05-31 Methods of treating breast cancer

Country Status (12)

Country Link
US (1) US20240269135A1 (https=)
EP (1) EP4346828A1 (https=)
JP (1) JP2024520142A (https=)
KR (1) KR20240016344A (https=)
CN (1) CN118139624A (https=)
AU (1) AU2022286616A1 (https=)
BR (1) BR112023025003A2 (https=)
CA (1) CA3220751A1 (https=)
CL (1) CL2023003533A1 (https=)
IL (1) IL308684A (https=)
MX (1) MX2023014420A (https=)
WO (1) WO2022253800A1 (https=)

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL1633724T3 (pl) 2003-03-12 2011-10-31 Kudos Pharm Ltd Pochodne ftalazynonu

Also Published As

Publication number Publication date
JP2024520142A (ja) 2024-05-21
MX2023014420A (es) 2024-04-23
CN118139624A (zh) 2024-06-04
WO2022253800A1 (en) 2022-12-08
US20240269135A1 (en) 2024-08-15
KR20240016344A (ko) 2024-02-06
BR112023025003A2 (pt) 2024-02-20
AU2022286616A1 (en) 2024-01-18
IL308684A (en) 2024-01-01
EP4346828A1 (en) 2024-04-10
CL2023003533A1 (es) 2024-06-28

Similar Documents

Publication Publication Date Title
Hong et al. Breast cancer: an up‐to‐date review and future perspectives
Campone et al. Vepdegestrant, a PROTAC estrogen receptor degrader, in advanced breast cancer
Catenacci et al. Rilotumumab plus epirubicin, cisplatin, and capecitabine as first-line therapy in advanced MET-positive gastric or gastro-oesophageal junction cancer (RILOMET-1): a randomised, double-blind, placebo-controlled, phase 3 trial
De Placido et al. Adjuvant anastrozole versus exemestane versus letrozole, upfront or after 2 years of tamoxifen, in endocrine-sensitive breast cancer (FATA-GIM3): a randomised, phase 3 trial
Loibl et al. Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: a randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE)
Benson et al. Early breast cancer
André et al. Everolimus for women with trastuzumab-resistant, HER2-positive, advanced breast cancer (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 trial
Venturini et al. Dose-dense adjuvant chemotherapy in early breast cancer patients: results from a randomized trial
Huang et al. Evaluation of pathologic complete response as a surrogate for long-term survival outcomes in triple-negative breast cancer
Jwa et al. Locoregional recurrence by tumor biology in breast cancer patients after preoperative chemotherapy and breast conservation treatment
Mowad et al. Does obesity have an effect on outcomes in triple-negative breast cancer?
Edwards et al. Topotecan, pegylated liposomal doxorubicin hydrochloride, paclitaxel, trabectedin and gemcitabine for advanced recurrent or refractory ovarian cancer: a systematic review and economic evaluation
Albanell et al. Palbociclib rechallenge for hormone receptor–positive/HER-negative advanced breast cancer: findings from the phase II BioPER trial
Aurilio et al. Oral metronomic cyclophosphamide and methotrexate plus fulvestrant in advanced breast cancer patients: A mono‐institutional case‐cohort report
Yu et al. Cyclophosphamide-free adjuvant chemotherapy for ovarian protection in young women with breast cancer: a randomized phase 3 trial
Santa-Maria et al. Integrating immunotherapy in early-stage triple-negative breast cancer: Practical evidence-based considerations
Muto et al. Therapeutic options in thymomas and thymic carcinomas
Guerrieri-Gonzaga et al. Preliminary results on safety and activity of a randomized, double-blind, 2× 2 trial of low-dose tamoxifen and fenretinide for breast cancer prevention in premenopausal women
Kim et al. Clinical activity of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer: A phase IB/II study (KCSG BR18-16)
Liu et al. Optimizing immunotherapy for head and neck squamous cell carcinoma: recent advances and future directions
US20240269135A1 (en) Methods of treating breast cancer
Zhu et al. A retrospective comparison of trastuzumab plus cisplatin and trastuzumab plus capecitabine in elderly HER2-positive advanced gastric cancer patients
Psyrri Exceptional Response to Copanlisib in a Heavily Pretreated Patient WithPIK3CA-Mutated Metastatic Breast Cancer
Thomssen et al. AGO recommendations for diagnosis and treatment of patients with primary and metastatic breast cancer. Update 2011
Jin et al. Combined treatment of inetetamab plus pyrotinib and vinorelbine in managing advanced HER2-positive breast cancer patients (ILLUMINE): a multicenter, retrospective, real-world study

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250423

MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD

Year of fee payment: 4

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260423

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260423